Ropharma Bras risk profile
26 Normal where most of the sector sits
Measured 1 September 2026 from RPH's filed statements. Recomputed nightly.
26 (Normal), driven by Cash conversion at 49, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 28 | Normal | Stable | Average daily turnover — $3.1K |
| Operating pressure | 39 | Normal | Stable | Costs outgrowing revenue — -0.6 percentage points |
| Cash conversion | 49 | Elevated | Worsening | Capital spending against operating cash — 0.43x |
| Leverage and coverage | 40 | Elevated | Easing | Net debt to EBITDA — 2.54x |
| Competitive position | 7 | Contained | Stable | Revenue-growth gap against peers — +43.0 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.